MedImmune statement on MedImmune vs. Genentech Supreme Court decision

MedImmune issued the following statement regarding today's U.S. Supreme Court decision in MedImmune, Inc. vs. Genentech, Inc. et al.:

By granting MedImmune's appeal, the U.S. Supreme Court has brought further clarity to the patent litigation process -- specifically, the use of declaratory judgments by licensees of questionable patents.

The Court's decision means MedImmune is free to pursue its complaint regarding non-infringement, invalidity, and unenforceability of the Cabilly II patent. We intend to do so vigorously and are confident that our position will prevail.

We appreciate the support MedImmune's position on this issue received in the amicus briefs filed by various parties, including the U.S. Solicitor General; the General Counsel of the U.S. Patent & Trademark Office; the Generic Pharmaceuticals Association; three intellectual property professors; the Natural Resources Defense Counsel, and legal counsel for Medtronic, Inc.

MedImmune strives to provide better medicines to patients, new medical options for physicians, rewarding careers to employees, and increased value to shareholders. Dedicated to advancing science and medicine to help people live better lives, the company is focused on the areas of infectious diseases, cancer and inflammatory diseases. MedImmune is headquartered in Maryland and has more than 2,500 employees worldwide.